SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SIBIA Neurosciences (SIBI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Czechsinthemail who wrote (57)8/12/1997 10:36:00 PM
From: Czechsinthemail   of 579
 
Here's a Dow Jones version of the Lilly story:

8/11/97 Sibia Neurosciences Says Research Pact With Eli Lilly To End

LA JOLLA, Calif. -(Dow Jones)- Sibia Neurosciences Inc. said Monday its research agreement with Eli Lilly & Co. for neuronal voltage-gated calcium channels, or VGCCs, will end in October.
VGCCs are one of the primary pathways through which calcium ions enter nerve cells, the company said, and modulating VGCCs may lead to therapies for nervous system disorders. Calcium ions wreck havoc on nerve cells.
Sibia said the last extension of the May 1992 pact reduced research funding it received from Lilly, and so Sibia views the financial impact of the collaboration's end as "minimal."
Sibia said it will receive milestone payments and royalties on sales of products commercialized by Lilly, and is free to develop VGCC compounds it discovers on its own or with other partners.
Sibia said it and Lilly will independently pursue discovery and development of drug leads that act on VGCC drug targets identified under the collaboration.
The company said it is "optimistic" that Lilly will select a clinical candidate based on the program "in the near term."
Sibia also said it has identified several "promising" VGCC compounds that may create other opportunities for partnerships.

Sounds like there may be more good news in this than I'd originally thought. It would certainly be nice if Lilly follows up on one of the prospects for clinicals, and perhaps SIBI has some leads for new partnership agreements.

Baird
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News